KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBT Margin: 2020-2025

Historic EBT Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -3,135.27%.

  • Recursion Pharmaceuticals' EBT Margin fell 276844.00% to -3,135.27% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,638.15%, marking a year-over-year decrease of 105066.00%. This contributed to the annual value of -789.93% for FY2024, which is 4483.00% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported EBT Margin of -3,135.27% as of Q3 2025, which was down 250.61% from -894.23% recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year EBT Margin high stood at -366.82% for Q3 2024, and its period low was -3,935.31% during Q4 2024.
  • Moreover, its 3-year median value for EBT Margin was -883.10% (2023), whereas its average is -1,278.48%.
  • In the last 5 years, Recursion Pharmaceuticals' EBT Margin soared by 2,938,181bps in 2021 and then slumped by 304,413bps in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' EBT Margin stood at -2,564.55% in 2021, then skyrocketed by 211,864bps to -445.91% in 2022, then slumped by 44,527bps to -891.18% in 2023, then slumped by 304,413bps to -3,935.31% in 2024, then plummeted by 276,844bps to -3,135.27% in 2025.
  • Its last three reported values are -3,135.27% in Q3 2025, -894.23% for Q2 2025, and -1,374.33% during Q1 2025.